2023 World Conference on Lung Cancer (Posters)-P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy

P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy - PDF(Abstract)

Back to course

Pdf Summary

This study investigated the stability of the gut microbiome in non-small cell lung cancer (NSCLC) patients undergoing chemoradiotherapy (CCRT) and its association with progression-free survival (PFS). Metagenome analysis was performed on fecal samples from 19 NSCLC patients at four timepoints throughout CCRT. The stability of the microbiota was estimated using microbiota stability assessment via iterative clustering. Patients were divided into two groups based on the median stability coefficients (mS score) of the core microbiota: the high stability (HS) group and the low stability (LS) group. <br /><br />The results showed that the gut microbiota in the HS group had less inter-patient variation compared to the LS group. In probiotics analysis, the HS group had a higher Simpson index on the genus and species level. Faecalibacterium and Stenotrophomonas were enriched in the HS group, while Bifidobacterium, Ruminococcus, and Vibrio were enriched in the LS group at baseline. <br /><br />Further analysis revealed that Faecalibacterium prausnitzii was the most abundant species of probiotics, which was enriched in the HS group. However, there was no significant difference in taxonomic composition and diversity of pathogens between the two groups. <br /><br />Clinical analysis showed that higher stability of the gut microbiome was associated with longer PFS in NSCLC patients. <br /><br />The study concludes that higher gut microbiome stability may be associated with better prognosis in NSCLC patients. Probiotics diversity and composition may help maintain the stability of the gut microbiome. Further validation is needed, but these findings could potentially lead to new therapeutic options for NSCLC patients.

Asset Subtitle

FangJie Liu

Meta Tag

Speaker FangJie Liu

Topic Pathology & Biomarkers: Prognostic Biomarkers

Keywords

gut microbiome

non-small cell lung cancer

NSCLC

chemoradiotherapy

CCRT

progression-free survival

metagenome analysis

microbiota stability assessment

probiotics analysis

Faecalibacterium prausnitzii